Crescita Therapeutics (CTX) Stock Price, News & Analysis

Company Overview

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including Multiplexed Molecular Penetration Enhancers (MMPE) and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription portfolio offers dermocosmetic products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare to treat mild acne, aging, dehydration, pigmentation, sensitivity, and rosacea under the Laboratoire Dr Renaud brand; and provides medical aesthetics under Pro-Derm and Alyria brands, for non-invasive and minimally invasive procedures or skincare treatments. In addition, it distributes NCTF Boost 135 HA, a skin revitalization solution; Obagi Medical products; and ART FILLER, hyaluronic acid-based dermal fillers. The company has a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.

Key Stats

• Today's Range: C$0.62 to C$0.64
• 50-Day Range: C$0.56 to C$0.64
• 52-Week Range: C$0.36 to C$0.69
• Volume: 2,020 shs
• Average Volume: 22,788 shs
• Market Capitalization: C$12.40 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CTX Stock Analysis - Frequently Asked Questions

How have CTX shares performed this year?

Crescita Therapeutics' stock was trading at C$0.49 at the beginning of 2024. Since then, CTX shares have increased by 30.6% and is now trading at C$0.64.
View the best growth stocks for 2024 here.

How do I buy shares of Crescita Therapeutics?

Shares of CTX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What other stocks do shareholders of Crescita Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescita Therapeutics investors own include Baytex Energy (BTE), Argonaut Gold (AR), Birchcliff Energy (BIR), CBTX (CBTX), Crescent Point Energy (CPG), Enbridge (ENB) and IMV (IMV).

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: N/A
• Current Symbol: TSE:CTX
• CUSIP: N/A
• CIK: N/A
• Web: www.crescitatherapeutics.com
• Phone: +1-905-6734295
• Fax: N/A
• Employees: 62
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): C($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: C$-2,980,000.00
• Net Margins: -17.72%
• Pretax Margin: N/A
• Return on Equity: -15.79%
• Return on Assets: -8.26%

Debt

• Debt-to-Equity Ratio: 6.02
• Current Ratio: 3.37
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: C$16.84 million
• Price / Sales: 0.74
• Cash Flow: C$0.53 per share
• Price / Cash Flow: 1.20
• Book Value: C$0.89 per share
• Price / Book: 0.72

Miscellaneous

• Outstanding Shares: 19,380,000
• Free Float: N/A
• Market Cap: C$12.40 million
• Optionable: Not Optionable
• Beta: 1.69